AUVI-Q vs. Other Epinephrine Auto-Injector Prescription Was Associated With Reduced Inpatient Hospitalizations for Anaphylaxis in a US Retrospective Commercial Claims Analysis
Author(s)
Vlad Zah, DPhil1, Erin Hulbert, MBA MSc2, Michelle Vu, PharmD MPh2, Erin Buysman, MSc2, Rachael Griffiths, PhD3;
1ZRx Outcomes Research, Inc., Health Economist, Mississauga, ON, Canada, 2Optum Life Sciences, Minneapolis, MN, USA, 3kaleo, Inc., Richmond, VA, USA
1ZRx Outcomes Research, Inc., Health Economist, Mississauga, ON, Canada, 2Optum Life Sciences, Minneapolis, MN, USA, 3kaleo, Inc., Richmond, VA, USA
OBJECTIVES: To compare anaphylaxis hospitalization rates among US patients prescribed AUVI-Q (epinephrine injection, USP), an epinephrine auto-injector (EAI) designed with audible and visible cues, a compact size, and an auto-retractable needle, versus Other EAIs.
METHODS: This US retrospective commercial claims analysis was performed in the Optum Research Database. Between January and December 2023, eligible patients were identified as those with at least one EAI claim, while anaphylaxis events were defined as medical claims with anaphylaxis-specific diagnostic codes, employing the previously validated Harduar-Morano algorithm. Prior prescription of EAIs was identified during a 1-year look-back period before the anaphylaxis event. Anaphylaxis-related hospitalizations were defined as inpatient admissions occurring within 90 days of an anaphylaxis event, excluding cases involving sepsis or immunocompromise.
RESULTS: The final cohort consisted of 10,130 AUVI-Q and 52,094 Other EAI patients. Patients prescribed AUVI-Q were younger (mean 18.93 vs. 28.48 years) and a larger proportion were male (51.97% vs. 45.73%) compared to the Other EAI patients. There were 2,609 anaphylaxis events among AUVI-Q patients vs. 7,354 Other EAI patients. Among them, inpatient hospitalizations related to anaphylaxis occurred for 4 AUVI-Q and 27 Other EAI patients. The rate of inpatient hospitalizations per patient was 0.00039 for AUVI-Q and 0.00052 for Other EAIs, with a 23.81% relative rate reduction for the AUVI-Q cohort. The rate of inpatient hospitalizations per anaphylaxis event was 0.00153 for AUVI-Q and 0.00367 for Other EAIs, with a 58.24% relative rate reduction for the AUVI-Q cohort. The EAI utilization rate per patient was 1.316 for AUVI-Q vs. 1.256 for Other EAIs, with a 1.047 utilization rate ratio.
CONCLUSIONS: Inpatient hospitalizations for anaphylaxis were lower among patients prescribed AUVI-Q vs. Other EAIs in this cohort of US patients in a commercial claims database.
METHODS: This US retrospective commercial claims analysis was performed in the Optum Research Database. Between January and December 2023, eligible patients were identified as those with at least one EAI claim, while anaphylaxis events were defined as medical claims with anaphylaxis-specific diagnostic codes, employing the previously validated Harduar-Morano algorithm. Prior prescription of EAIs was identified during a 1-year look-back period before the anaphylaxis event. Anaphylaxis-related hospitalizations were defined as inpatient admissions occurring within 90 days of an anaphylaxis event, excluding cases involving sepsis or immunocompromise.
RESULTS: The final cohort consisted of 10,130 AUVI-Q and 52,094 Other EAI patients. Patients prescribed AUVI-Q were younger (mean 18.93 vs. 28.48 years) and a larger proportion were male (51.97% vs. 45.73%) compared to the Other EAI patients. There were 2,609 anaphylaxis events among AUVI-Q patients vs. 7,354 Other EAI patients. Among them, inpatient hospitalizations related to anaphylaxis occurred for 4 AUVI-Q and 27 Other EAI patients. The rate of inpatient hospitalizations per patient was 0.00039 for AUVI-Q and 0.00052 for Other EAIs, with a 23.81% relative rate reduction for the AUVI-Q cohort. The rate of inpatient hospitalizations per anaphylaxis event was 0.00153 for AUVI-Q and 0.00367 for Other EAIs, with a 58.24% relative rate reduction for the AUVI-Q cohort. The EAI utilization rate per patient was 1.316 for AUVI-Q vs. 1.256 for Other EAIs, with a 1.047 utilization rate ratio.
CONCLUSIONS: Inpatient hospitalizations for anaphylaxis were lower among patients prescribed AUVI-Q vs. Other EAIs in this cohort of US patients in a commercial claims database.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
RWD68
Topic
Real World Data & Information Systems
Topic Subcategory
Health & Insurance Records Systems
Disease
SDC: Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory), SDC: Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)